Downmodulation of ERK protein kinase activity inhibits VEGF secretion by human myeloma cells and myeloma-induced angiogenesis

[1]  P. Pelicci,et al.  Downmodulation of ERK activity inhibits the proliferation and induces the apoptosis of primary acute myelogenous leukemia blasts , 2003, Leukemia.

[2]  R. Bataille,et al.  Proangiogenic properties of human myeloma cells: production of angiopoietin-1 and its potential relationship to myeloma-induced angiogenesis. , 2003, Blood.

[3]  J. McCubrey,et al.  Signal transduction mediated by the Ras/Raf/MEK/ERK pathway from cytokine receptors to transcription factors: potential targeting for therapeutic intervention , 2003, Leukemia.

[4]  L. Platanias.  Map kinase signaling pathways and hematologic malignancies. , 2003, Blood.

[5]  J. McCubrey,et al.  Requirement for the PI3K/Akt pathway in MEK1-mediated growth and prevention of apoptosis: identification of an Achilles heel in leukemia , 2003, Leukemia.

[6]  G. Semenza,et al.  Vascular endothelial growth factor gene expression in colon cancer cells exposed to prostaglandin E2 is mediated by hypoxia-inducible factor 1. , 2003, Cancer research.

[7]  J. McCubrey,et al.  Effects of the RAF/MEK/ERK and PI3K/AKT signal transduction pathways on the abrogation of cytokine-dependence and prevention of apoptosis in hematopoietic cells , 2003, Oncogene.

[8]  J. McCubrey,et al.  Regulation of cell cycle progression and apoptosis by the Ras/Raf/MEK/ERK pathway (Review). , 2003, International journal of oncology.

[9]  Masaharu Akiyama,et al.  Targeting p38 MAPK inhibits multiple myeloma cell growth in the bone marrow milieu. , 2003, Blood.

[10]  G. Semenza,et al.  Vascular Endothelial Growth Factor Gene Expression in Colon Cancer Cells Exposed to Prostaglandin E 2 Is Mediated by Hypoxia-inducible Factor 1 1 , 2003 .

[11]  T. Hideshima,et al.  Molecular mechanisms of novel therapeutic approaches for multiple myeloma , 2002, Nature Reviews Cancer.

[12]  P. Dent,et al.  Combined treatment with the checkpoint abrogator UCN-01 and MEK1/2 inhibitors potently induces apoptosis in drug-sensitive and -resistant myeloma cells through an IL-6-independent mechanism. , 2002, Blood.

[13]  Bin Zhang,et al.  Proliferation of IL‐6‐independent multiple myeloma does not require the activity of extracellular signal‐regulated kinases (ERK1/2) , 2002, Journal of cellular physiology.

[14]  S. Cook,et al.  Cell-cycle arrest by PD184352 requires inhibition of extracellular signal-regulated kinases (ERK) 1/2 but not ERK5/BMK1. , 2002, The Biochemical journal.

[15]  M. Konopleva,et al.  Synergistic induction of apoptosis by simultaneous disruption of the Bcl-2 and MEK/MAPK pathways in acute myelogenous leukemia. , 2002, Blood.

[16]  De Johnson,et al.  Importance of MEK-1/-2 signaling in monocytic and granulocytic differentiation of myeloid cell lines , 2002, Leukemia.

[17]  J. McCubrey,et al.  The Raf/MEK/ERK signal transduction cascade as a target for chemotherapeutic intervention in leukemia , 2002, Leukemia.

[18]  M. Cobb,et al.  Pharmacological inhibitors of MAPK pathways. , 2002, Trends in pharmacological sciences.

[19]  P. Richardson,et al.  Novel therapies targeting the myeloma cell and its bone marrow microenvironment. , 2001, Seminars in oncology.

[20]  N. Munshi,et al.  Increased bone marrow microvessel density in newly diagnosed multiple myeloma carries a poor prognosis. , 2001, Seminars in oncology.

[21]  W. Bellamy.  Expression of vascular endothelial growth factor and its receptors in multiple myeloma and other hematopoietic malignancies. , 2001, Seminars in oncology.

[22]  D. Chauhan,et al.  Biologic sequelae of interleukin-6 induced PI3-K/Akt signaling in multiple myeloma , 2001, Oncogene.

[23]  E. Estey,et al.  Therapeutic targeting of the MEK/MAPK signal transduction module in acute myeloid leukemia. , 2001, The Journal of clinical investigation.

[24]  Philip R. Cohen,et al.  Effects of MAP kinase cascade inhibitors on the MKK5/ERK5 pathway , 2001, FEBS letters.

[25]  K. Anderson,et al.  Vascular endothelial growth factor triggers signaling cascades mediating multiple myeloma cell growth and migration. , 2001, Blood.

[26]  J. McCubrey,et al.  Effects of inducible MEK1 activation on the cytokine dependency of lymphoid cells , 2001, Leukemia.

[27]  M. Morgan,et al.  Cell-cycle-dependent activation of mitogen-activated protein kinase kinase (MEK-1/2) in myeloid leukemia cell lines and induction of growth inhibition and apoptosis by inhibitors of RAS signaling. , 2001, Blood.

[28]  P. Pelicci,et al.  Expression and activation of SHC/MAP kinase pathway in primary acute myeloid leukemia blasts. , 2001, The hematology journal : the official journal of the European Haematology Association.

[29]  J. McCubrey,et al.  Interactions between the PI3K and Raf signaling pathways can result in the transformation of hematopoietic cells. , 2001, Cancer detection and prevention.

[30]  J. Sebolt-Leopold.  Development of anticancer drugs targeting the MAP kinase pathway , 2000, Oncogene.

[31]  W. Berdel,et al.  Vascular endothelial growth factor and interleukin-6 in paracrine tumor-stromal cell interactions in multiple myeloma. , 2000, Blood.

[32]  M. Hallett,et al.  The MEK inhibitor, PD98059, reduces survival but does not block acute myeloid leukemia blast maturation in vitro , 2000, European journal of haematology.

[33]  J. McCubrey,et al.  Differential abilities of the Raf family of protein kinases to abrogate cytokine dependency and prevent apoptosis in murine hematopoietic cells by a MEK1-dependent mechanism , 2000, Leukemia.

[34]  P. Pelicci,et al.  Selective expression and constitutive phosphorylation of Src-homology-2 and collagen-homology domains proteins in the CD34+ fraction of chronic myelogenous leukemias , 2000 .

[35]  P. Pelicci,et al.  Selective Expression and Constitutive Phosphorylation of SHC Proteins in the CD34 1 Fraction of Chronic Myelogenous Leukemias 1 , 2000 .

[36]  P. Cohen,et al.  Specificity and mechanism of action of some commonly used protein kinase inhibitors. , 2000, The Biochemical journal.

[37]  L. Ellis,et al.  Extracellular signal-regulated kinase activation is required for up-regulation of vascular endothelial growth factor by serum starvation in human colon carcinoma cells. , 1999, Cancer research.

[38]  Alan R. Saltiel,et al.  Blockade of the MAP kinase pathway suppresses growth of colon tumors in vivo , 1999, Nature Medicine.

[39]  G. Woude,et al.  MEK Wars, a new front in the battle against cancer , 1999, Nature Medicine.

[40]  J. Hahn,et al.  Constitutive activation of extracellular signal-regulated kinase in human acute leukemias: combined role of activation of MEK, hyperexpression of extracellular signal-regulated kinase, and downregulation of a phosphatase, PAC1. , 1999, Blood.

[41]  D. Ribatti,et al.  Bone marrow neovascularization, plasma cell angiogenic potential, and matrix metalloproteinase-2 secretion parallel progression of human multiple myeloma. , 1999, Blood.

[42]  R. Schmidt-Ullrich,et al.  The roles of signaling by the p42/p44 mitogen-activated protein (MAP) kinase pathway; a potential route to radio- and chemo-sensitization of tumor cells resulting in the induction of apoptosis and loss of clonogenicity , 1998, Leukemia.

[43]  M. Urashima,et al.  IL-6 triggers cell growth via the Ras-dependent mitogen-activated protein kinase cascade. , 1997, Journal of immunology.

[44]  H. Saito,et al.  Constitutive activation of mitogen-activated protein kinase pathway in acute leukemia cells , 1997, Leukemia.

[45]  M. Urashima,et al.  Interleukin-6 inhibits Fas-induced apoptosis and stress-activated protein kinase activation in multiple myeloma cells. , 1997, Blood.

[46]  Philip R. Cohen,et al.  FGF and stress regulate CREB and ATF‐1 via a pathway involving p38 MAP kinase and MAPKAP kinase‐2. , 1996, The EMBO journal.

[47]  Philip R. Cohen,et al.  PD 098059 Is a Specific Inhibitor of the Activation of Mitogen-activated Protein Kinase Kinase in Vitro and in Vivo(*) , 1995, The Journal of Biological Chemistry.

[48]  M. Borrello,et al.  Constitutive phosphorylation of Shc proteins in human tumors. , 1995, Oncogene.

[49]  A. Bridges,et al.  A synthetic inhibitor of the mitogen-activated protein kinase cascade. , 1995, Proceedings of the National Academy of Sciences of the United States of America.